Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carcinoma, Neuroendocrine Written informed consent in accordance with federal, local, and institutional guidelines Age ≥18 years Patients must have a tissue diagnosis of any of the following Small cell lung cancer (SCLC) or poorly differentiated gastroenteropancreatic neuroendocrine tumor (GEP-NET) Poorly differentiated metastatic neuroendocrine tumors of unknown primary origin Measurable disease: Any primary and/or metastatic mass reproducibly measurable in one or two diameters by 1.1 parameters by cat scan (CT) scan Objective evidence of tumor progression within 4 months prior to study entry, as defined by serial cat scan (CT) per 1.1 criteria. (At least a 20% increase in the sum of diameters of target lesions. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression) Patients must have received at least one prior line of chemotherapy and must have exhausted any other standard-of-care treatment option Prior radiation and surgery is allowed. At least 3 weeks should have elapsed from surgery, chemotherapy, hepatic embolization/ chemoembolization or radioactive isotopes (i.e. Yttrium 90). In any case, disease progression must be documented after treatment Eastern Cooperative Oncology Group (ECOG) performance status of 0-1  Patients who are pregnant or lactating Patients with the following tumor types: lung carcinoid, pheochromocytomas, paragangliomas, medullary thyroid carcinomas, any other tumors with neuroendocrine features not listed in the Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤3 weeks prior to C1D1 Major surgery ≤3 weeks prior to C1D1 Unstable cardiovascular function Congestive heart failure (CHF) of NYHA Class ≥3 OR Myocardial infarction (MI) within 3 months Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; patients with controlled infection or on prophylactic antibiotics are permitted in the study Known to be human immunodeficiency virus (HIV) seropositive Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV RNA) or HBsAg (HBV surface antigen)